메뉴 건너뛰기




Volumn 72, Issue 15, 2012, Pages 2023-2032

Carfilzomib: In relapsed, or relapsed and refractory, multiple myeloma

Author keywords

Adis Drug Profiles; Carfilzomib; Multiple myeloma; Myeloma

Indexed keywords

CARFILZOMIB; ONO 7057; UNCLASSIFIED DRUG;

EID: 84867317695     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11209010-000000000-00000     Document Type: Article
Times cited : (26)

References (28)
  • 1
    • 85081773249 scopus 로고    scopus 로고
    • [online]. Available from URL [Accessed 2012 Sep 11]
    • The Merck Manual: multiple myeloma [online]. Available from URL: http://www.merckmanuals.com/professional/hematology-and-oncology/plasma cell-disorders/multiple myeloma.html [Accessed 2012 Sep 11]
    • The Merck Manual: Multiple Myeloma
  • 2
    • 85081769820 scopus 로고    scopus 로고
    • American Cancer Society. Multiple myeloma [online]. Available from URL: [Accessed 2012 Sep 11]
    • American Cancer Society. Multiple myeloma [online]. Available from URL: http://www.cancer.org/Cancer/Multi pleMyeloma/DetailedGuide/multiple-myeloma- key-statistics [Accessed 2012 Sep 11]
  • 4
    • 41949130070 scopus 로고    scopus 로고
    • Improved survival in multiple myeloma and the impact of novel therapies
    • Mar 1
    • Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008 Mar 1; 111 (5): 2516-20
    • (2008) Blood , vol.111 , Issue.5 , pp. 2516-2520
    • Kumar, S.K.1    Rajkumar, S.V.2    Dispenzieri, A.3
  • 5
    • 0032488846 scopus 로고    scopus 로고
    • The proteasome: Paradigm of a self-compartmentalizing protease
    • DOI 10.1016/S0092-8674(00)80929-0
    • Baumeister W, Walz J, Zü hl F, et al. The proteasome: paradigm of a self-compartmentalizing protease. Cell 1998 Feb 6; 92 (3): 367-80 (Pubitemid 28093014)
    • (1998) Cell , vol.92 , Issue.3 , pp. 367-380
    • Baumeister, W.1    Walz, J.2    Zuhl, F.3    Seemuller, E.4
  • 7
    • 65549136174 scopus 로고    scopus 로고
    • Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells
    • Mar
    • Fuchs O, Provaznikova D, Marinov I, et al. Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells. Cardiovasc Hematol Disord Drug Targets 2009 Mar; 9 (1): 62-77
    • (2009) Cardiovasc Hematol Disord Drug Targets , vol.9 , Issue.1 , pp. 62-77
    • Fuchs, O.1    Provaznikova, D.2    Marinov, I.3
  • 8
    • 79955498420 scopus 로고    scopus 로고
    • Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: A link to clinical adverse events
    • May 1
    • Arastu-Kapur S, Anderl JL, Kraus M, et al. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res 2011 May 1; 17 (9): 2734-43
    • (2011) Clin Cancer Res , vol.17 , Issue.9 , pp. 2734-2743
    • Arastu-Kapur, S.1    Anderl, J.L.2    Kraus, M.3
  • 10
    • 77954125336 scopus 로고    scopus 로고
    • Peripheral neuropathy during bortezomib treatment of multiple myeloma: A review of recent studies
    • Jul
    • Cavaletti G, Jakubowiak AJ. Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies. Leuk Lymphoma 2010 Jul; 51 (7): 1178-87
    • (2010) Leuk Lymphoma , vol.51 , Issue.7 , pp. 1178-1187
    • Cavaletti, G.1    Jakubowiak, A.J.2
  • 11
    • 85081764557 scopus 로고    scopus 로고
    • US FDA [online]. Available from URL: [Accessed 2012 Sep 11]
    • US FDA. Kyprolis (carfilzomib) for injection: US prescribing information [online]. Available from URL: http://www. accessdata.fda.gov/drugsatfda docs/label/2012/202714lbl.pdf [Accessed 2012 Sep 11]
    • Kyprolis (Carfilzomib) for Injection: US Prescribing Information
  • 12
    • 70350708810 scopus 로고    scopus 로고
    • Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome
    • Oct 15
    • Parlati F, Lee SJ, Aujay M, et al. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood 2009 Oct 15; 114 (16): 3439-47
    • (2009) Blood , vol.114 , Issue.16 , pp. 3439-3447
    • Parlati, F.1    Lee, S.J.2    Aujay, M.3
  • 13
    • 84865712581 scopus 로고    scopus 로고
    • A phase 1 singleagent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma
    • Jul 3
    • Alsina M, Trudel S, Furman RR, et al. A phase 1 singleagent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. Clin Cancer Res. Epub 2012 Jul 3
    • (2012) Clin Cancer Res. Epub
    • Alsina, M.1    Trudel, S.2    Furman, R.R.3
  • 15
    • 72549116835 scopus 로고    scopus 로고
    • Aphase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies
    • Nov 15
    • O'Connor OA, Stewart AK, Vallone M, et al. Aphase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res 2009 Nov 15; 15 (22): 7085-91
    • (2009) Clin Cancer Res , vol.15 , Issue.22 , pp. 7085-7091
    • O'Connor, O.A.1    Stewart, A.K.2    Vallone, M.3
  • 16
    • 80053148350 scopus 로고    scopus 로고
    • Pharmacokinetics pharmacodynamics metabolism distribution and excretion of carfilzomib in rats
    • Oct
    • Yang J, Wang Z, Fang Y, et al. Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats. Drug Metab Dispos 2011 Oct; 39 (10): 1873-82
    • (2011) Drug Metab Dispos , vol.39 , Issue.10 , pp. 1873-1882
    • Yang, J.1    Wang, Z.2    Fang, Y.3
  • 17
    • 84867323972 scopus 로고    scopus 로고
    • Carfilzomib pharmacokinetics safety and activity in patients with relapsed or refractory multiple myeloma and renal dysfunction: Final results [abstract no. 0890]
    • Jun
    • Niesvizky R, Vij R, Martin T, et al. Carfilzomib pharmacokinetics, safety, and activity in patients with relapsed or refractory multiple myeloma and renal dysfunction: final results [abstract no. 0890]. Haematologica 2011 Jun; 96 Suppl. 2: 370-1
    • (2011) Haematologica , vol.96 , Issue.SUPPL. 2 , pp. 370-371
    • Niesvizky, R.1    Vij, R.2    Martin, T.3
  • 18
    • 84875364354 scopus 로고    scopus 로고
    • Final results of PX-171-003-A0, part 1 of an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM) [abstract no. 8504]
    • May 20
    • Jagannath S, Vij R, Stewart K, et al. Final results of PX-171-003-A0, part 1 of an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM) [abstract no. 8504]. J Clin Oncol 2009 May 20; 27 (15 Suppl.)
    • (2009) J Clin Oncol , vol.27 , Issue.15 SUPPL.
    • Jagannath, S.1    Vij, R.2    Stewart, K.3
  • 19
    • 84867295563 scopus 로고    scopus 로고
    • A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
    • Jul 25
    • Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. Epub 2012 Jul 25
    • (2012) Blood. Epub
    • Siegel, D.S.1    Martin, T.2    Wang, M.3
  • 20
    • 84865552564 scopus 로고    scopus 로고
    • An open-label, singlearm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib
    • Jul 30
    • Vij R, Siegel DS, Jagannath S, et al. An open-label, singlearm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol. Epub 2012 Jul 30
    • (2012) Br J Haematol. Epub
    • Vij, R.1    Siegel, D.S.2    Jagannath, S.3
  • 21
    • 84862507585 scopus 로고    scopus 로고
    • An open-label singlearm phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma
    • Jun 14
    • Vij R, Wang M, Kaufman JL, et al. An open-label, singlearm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood 2012 Jun 14; 119 (24): 5661-70
    • (2012) Blood , vol.119 , Issue.24 , pp. 5661-5670
    • Vij, R.1    Wang, M.2    Kaufman, J.L.3
  • 22
    • 85081762315 scopus 로고    scopus 로고
    • US FDA Oncologic Drugs Advisory Committee Meeting, June 20 [online]. Available from URL: [Accessed 2012 Sep 11]
    • US FDA. New Drug Application (NDA) 202714, carfilzomib (Kyprolis): Food and Drug Administration briefing document, Oncologic Drugs Advisory Committee Meeting, June 20, 2012 [online]. Available from URL: http://www.fda.gov/ downloads/AdvisoryCommittees/Committees MeetingMaterials/Drugs/ OncologicDrugsAdvisoryCommi ttee/UCM308563.pdf [Accessed 2012 Sep 11]
    • (2012) New Drug Application (NDA) 202714, Carfilzomib (Kyprolis): Food and Drug Administration Briefing Document
  • 24
    • 85081773214 scopus 로고    scopus 로고
    • A phase 1b/2 study of prolonged infusion carfilzomib in patients with relapsed and/or refractory (R/R) multiple myeloma: Updated efficacy and tolerability from the completed 20/56 mg/m2 expansion cohort of PX-171-007 [abstract no. 2930]
    • Dec 10-13; San Diego (CA)
    • Papadopoulos KP, Lee P, Singhal S, et al. A phase 1b/2 study of prolonged infusion carfilzomib in patients with relapsed and/or refractory (R/R) multiple myeloma: updated efficacy and tolerability from the completed 20/56 mg/m2 expansion cohort of PX-171-007 [abstract no. 2930]. 53rd Annual Meeting and Exposition of the American Society of Hematology; 2011 Dec 10-13; San Diego (CA)
    • (2011) 53rd Annual Meeting and Exposition of the American Society of Hematology
    • Papadopoulos, K.P.1    Lee, P.2    Singhal, S.3
  • 25
    • 85081768282 scopus 로고    scopus 로고
    • A summary of safety and efficacy data achieved with long-term carfilzomib (CFZ) treatment in patients with relapsed and/or refractory multiple myeloma (R/R Mm) [abstract no. 0302]
    • Jun 9-12; London
    • Siegel D, Kaufman JL, Wang M, et al. A summary of safety and efficacy data achieved with long-term carfilzomib (CFZ) treatment in patients with relapsed and/or refractory multiple myeloma (R/R Mm) [abstract no. 0302]. 16th Congress of the European Hematology Association; 2011 Jun 9-12; London
    • (2011) 16th Congress of the European Hematology Association
    • Siegel, D.1    Kaufman, J.L.2    Wang, M.3
  • 26
    • 85081771781 scopus 로고    scopus 로고
    • US FDA 202714, with the proposed trade name Kyprolis, carfilzomib, for injection [online]. Available from URL: [Accessed 2012 Sep 11]
    • US FDA. Transcript of the Oncologic Drugs Advisory Committee discussion of the New Drug Application, 202714, with the proposed trade name Kyprolis, carfilzomib, for injection [online]. Available from URL: http://www.fda.gov/ downloads/AdvisoryCommittees/Committees MeetingMaterials/Drugs/ OncologicDrugsAdvisoryCommi ttee/UCM314709.pdf [Accessed 2012 Sep 11]
    • Transcript of the Oncologic Drugs Advisory Committee Discussion of the New Drug Application
  • 27
    • 85081761752 scopus 로고    scopus 로고
    • Hematologic safety data of single-agent carfilzomib in relapsed and/or refractory multiple myeloma: Pooled data from four phase 2 studies [abstract no. 8086]
    • May 30
    • Nooka A, Badros A, Patel P, et al. Hematologic safety data of single-agent carfilzomib in relapsed and/or refractory multiple myeloma: pooled data from four phase 2 studies [abstract no. 8086]. J Clin Oncol 2012 May 30; 30 (15 Suppl.)
    • (2012) J Clin Oncol , vol.30 , Issue.15 SUPPL.
    • Nooka, A.1    Badros, A.2    Patel, P.3
  • 28
    • 84867319090 scopus 로고    scopus 로고
    • Carfilzomib dose and schedule need not be adjusted for baseline renal dysfunction including patients on hemodialysis [abstract no. 0844]
    • Jun 1
    • Harvey RD, Lonial S, Patel P, et al. Carfilzomib dose and schedule need not be adjusted for baseline renal dysfunction, including patients on hemodialysis [abstract no. 0844]. Haematologica 2012 Jun 1; 97 Suppl. 1: 346
    • (2012) Haematologica , vol.97 , Issue.SUPPL. 1 , pp. 346
    • Harvey, R.D.1    Lonial, S.2    Patel, P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.